Tokyo, London 5 October, 2005 – Sosei Co. Ltd. [4565, Tokyo Stock exchange MOTHERS index] acquired the license for the intellectual property rights related to the hepatocyte growth factor (HGF), identified by Professor Toshikazu Nakamura, of Osaka University School of Medicine. These intellectual property rights were sub-licensed to Sumitomo Pharmaceuticals Company (now Dainippon Sumitomo Pharma Co., Ltd.).
Some of these related intellectual property rights act as a basic patent for using the HGF gene in gene therapy. A transfer of intellectual property rights has been made from Dainippon Sumitomo Pharma to MedGene Bioscience Co., Ltd (now AnGes MG, Inc.). Following this transfer Sosei now has the right to obtain part of the compensation which Dainippon Sumitomo Pharma will receive from AnGes MG, Inc.